Atrium Adverse Reactions

The adverse effects are reported in decreasing order of frequency within each system order class (SOC).
As with most neuromuscular blocking agents, the potential exists for undesirable effects suggestive of histamine release in susceptible patients.
In clinical trials (875 patients) reports of skin flushing ranged from 1% at doses up to 0.3 mg/kg, to 29% at doses of 0.6 mg/kg or greater. The incidence of transient hypotension ranged from 1 to 14% respectively for the corresponding dosages. (See table.)

Click on icon to see table/diagram/image

After prolonged administration of atracurium besilate in severely ill patients under intensive care, some incidences of muscle weakness and/or myopathy occurred. Most patients were concomitantly treated with corticosteroids. A causal relationship with atracurium therapy has not been established.
There have been rare reports of seizures in ICU patients who have been receiving atracurium concurrently with several other agents. These patients usually had one or more medical conditions predisposing to seizures (e.g. cranial trauma, cerebral oedema, viral encephalitis, hypoxic encephalopathy, uremia). In clinical trials, there appears to be no correlation between plasma laudanosine concentration and the occurrence of seizures.